211 related articles for article (PubMed ID: 23633635)
1. [Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
Fujita M; Goto T; Uchida K; Saiki S; Arima R
Hinyokika Kiyo; 2013 Mar; 59(3):183-8. PubMed ID: 23633635
[TBL] [Abstract][Full Text] [Related]
2. [Recrudescence of prostate cancer with low serum level of PSA and high serum level of CEA and CA19-9: a case report].
Yokoyama S; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
Hinyokika Kiyo; 2007 Jul; 53(7):485-7. PubMed ID: 17702183
[TBL] [Abstract][Full Text] [Related]
3. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
4. [Prostate cancer with high serum level of CEA and CA19-9: a case report].
Momma T; Kimura S; Saito S; Onoda N
Hinyokika Kiyo; 1998 Mar; 44(3):187-91. PubMed ID: 9589883
[TBL] [Abstract][Full Text] [Related]
5. M1 prostate cancer with a serum level of prostate-specific antigen less than 10 ng/mL.
Yamamoto S; Ito T; Akiyama A; Aizawa T; Miki M; Tachibana M
Int J Urol; 2001 Jul; 8(7):374-9. PubMed ID: 11442659
[TBL] [Abstract][Full Text] [Related]
6. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
[TBL] [Abstract][Full Text] [Related]
7. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
9. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
[TBL] [Abstract][Full Text] [Related]
10. [Prostate cancer of unknown primary origin with multiple lymph nodes metastasis; a case report].
Haraoka M; Takamuki M; Toyonaga Y; Tanaka M; Hanazawa K; Sakamoto Y; Horie S
Nihon Hinyokika Gakkai Zasshi; 2014 Oct; 105(4):212-7. PubMed ID: 25757353
[TBL] [Abstract][Full Text] [Related]
11. Metastatic prostate cancer with normal level of serum prostate-specific antigen.
Nishio R; Furuya Y; Nagakawa O; Fuse H
Int Urol Nephrol; 2003; 35(2):189-92. PubMed ID: 15072491
[TBL] [Abstract][Full Text] [Related]
12. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
13. [A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
Okajima K; Yamashita Y; Onuki T; Fujinami K; Senga Y; Goto A; Jinza S; Asakura T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1247-9. PubMed ID: 18633274
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen and carbohydrate antigen 19-9-producing adenocarcinoma of the prostate: report of an autopsy case.
Kodama S; Itoh H; Ide H; Kataoka H; Takehara T; Nagano M; Hamasuna R; Koono M; Osada Y
Urol Int; 1999; 63(3):193-7. PubMed ID: 10738193
[TBL] [Abstract][Full Text] [Related]
15. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
16. [Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report].
Ueda Y; Higuchii Y; Hashimoto T; Mitsui Y; Maruyamai T; Kondou N; Nojima M; Yamamoto S; Shincho M; Hirota S; Shima H
Hinyokika Kiyo; 2007 May; 53(5):327-30. PubMed ID: 17561720
[TBL] [Abstract][Full Text] [Related]
17. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
20. High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.
Shigeta K; Kosaka T; Kitano S; Yasumizu Y; Miyazaki Y; Mizuno R; Shinojima T; Kikuchi E; Miyajima A; Tanoguchi H; Hasegawa S; Oya M
Ann Surg Oncol; 2016 Nov; 23(12):4115-4122. PubMed ID: 27364499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]